Merck
RENFLEXIS
Manufacturer:
Merck
Name:
RENFLEXIS
HCPCS Code Descriptor:
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
Category:
Q Code
HCPCS:
Q5104
NDC(s):
78206-0162-01, 00006-4305-02
Primary Type:
Immunology Anti-TNF Biosimilar
Generic Status:
Multi-Source
Route of Administration:
Intravenous
About:
RENFLEXIS is an Immunology Anti-TNF Biosimilar drug manufactured by Merck and administered via the Intravenous route of administration. The Q Code: Q5104 is aligned to the drug RENFLEXIS.
Renflexis (infliximab) is a monoclonal antibody that is used to treat a range of inflammatory autoimmune disorders. Renflexis binds to tumor necrosis factor-alpha and hinders it from activating certain processes. This medication is administered via intravenous infusion over the course of multiple weeks. Renflexis is manufactured by Merck Sharp & Dohme and Organon and is biosimilar to Remicade (J1745). The Q Code that was assigned to this medication (Q5104) has been effective since April 2018. Patient assistance programs for this medication can be found through the Organon access program.